Ozmosi | Gadoteridol Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Gadoteridol

Alternative Names: gadoteridol, prohance, prohance multipack
Clinical Status: Inactive
Latest Update: 2025-07-16
Latest Update Note: Clinical Trial Update

Product Description

Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Gadoteridol)

Mechanisms of Action: Contrast Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Colombia | Croatia | Czech | Denmark | Estonia | Finland | France | Germany | Greece | Hungary | India | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated